KEGG   DRUG: Daclatasvir, asunaprevir and beclabuvir
Entry
D10882            Mixture   Drug                                   

Name
Daclatasvir, asunaprevir and beclabuvir;
Ximency (TN)
Component
(Daclatasvir dihydrochloride [DR:D10105] | Daclatasvir [DR:D10065]), Asunaprevir [DR:D10093], (Beclabuvir hydrochloride [DR:D10611] | Beclabuvir [DR:D10610])
Remark
Therapeutic category: 6250
ATC code: J05AP58
Efficacy
Antiviral
Comment
Daclatasvir is a substrate of CYP3A4 and P-glycoprotein (P-gp) , and it is an inhibitor of the following transporters: P-gp, OATP1B1, OATP1B3 and BCRP.
Asunaprevir is a substrate of CYP3A, P-gp and OATP1B1, and it is an inhibitor of CYP2D6, OATP1B1, OATP1B3 and P-gp and a inducer of CYP3A4.
Beclabuvir is a substrate of CYP3A, P-gp and BCRP, and it is an inhibitor of P-gp, BCRP, OATP1B1 and OATP1B3 and a inducer of CYP3A4.
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551]
Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599]
Interaction
CYP induction: CYP3A4 [HSA:1576]
Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP58 Daclatasvir, asunaprevir and beclabuvir
      D10882  Daclatasvir, asunaprevir and beclabuvir
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10882  Daclatasvir, asunaprevir and beclabuvir
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10882
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10882
 Drug transporters
  D10882
Other DBs
PubChem: 328082974
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system